via Queen’s University Belfast
Scientists at Queen’s University Belfast have discovered a new molecule which has the potential to prolong the life of individuals with cystic fibrosis (CF).
The molecule represents a possible future treatment and works by altering cellular ion channels resulting in improved airway hydration and significantly increased mucus clearance.
For individuals with CF, normal airway clearance mechanisms which keep the lungs free of infection are defective. As a result, a build-up of mucus occurs and predisposes the individual to chronic bacterial infection. The ensuing cycles of chronic infection and airway inflammation cause progressive destruction of the airways, which is ultimately fatal.
The innovative approach could reduce the frequency of these infections through a novel protease inhibitor which prevents activation of the epithelial sodium channel; ENaC.
The research involved a team of scientists from Queen’s University alongside colleagues at the Royal College of Surgeons in Ireland and the University of North Carolina, and was funded by The Cystic Fibrosis Trust.
Speaking about the breakthrough, Dr Lorraine Martin from the School of Pharmacy at Queen’s University Belfast, said: “This is an important finding which could provide a novel therapeutic opportunity relevant to all individuals with CF, as the targeting of ENaC is independent of their underlying CF mutation. This strategy could prevent the significant lung damage that results from chronic cycles of infection and inflammation, with potential impact on quality of life as well as life expectancy. This is a further example of Queen’s University’s research advancing knowledge and changing lives.”
Ed Owen, Chief Executive at the Cystic Fibrosis Trust, said: “We are thrilled with these initial findings and are excited to see how the next stage of preclinical testing progresses. We are pleased to have been able to fund this world class project at its early stage and welcome the drug development programme planned over the coming years. Research is the biggest single area of investment for the Cystic Fibrosis Trust and it’s wonderful to see projects like this making such positive progress in our fight for a life unlimited.”
Currently available pharmacological alternatives are only suitable for a small subset of patients depending on the disease-causing genetic mutation.
Learn more: QUEEN’S SCIENTISTS DEVELOP NEW TREATMENT TO PROLONG LIFE OF THOSE WITH CYSTIC FIBROSIS
The Latest on: Cystic Fibrosis
via Google News
The Latest on: Cystic Fibrosis
- Hartline To Serve As Great Strides’ Honorary Chairon January 17, 2022 at 1:00 pm
Cleveland community leader Steve Hartline will serve as honorary chairman of 2022 Great Strides, the Cystic Fibrosis Foundation’s largest national fundraising event for those with cystic fibrosis. The ...
- Lifesaving cystic fibrosis drug now approved for 6-11 year oldson January 17, 2022 at 5:39 am
The life-saving cystic fibrosis drug, Kaftrio, has been approved for use for many eligible children aged 6-11 in England, Wales, Scotland and Northern Ireland. This is a huge milestone in the Kaftrio ...
- Galway virtual cystic fibrosis clinic proves 'life changing' for someon January 14, 2022 at 1:32 am
An outpatient clinic at University Hospital Galway for patients with cystic fibrosis has more than doubled the numbers accessing physiotherapy services since going online.
- Wider Approval for Cystic Fibrosis 'Miracle' Drugon January 12, 2022 at 10:18 am
The MHRA extended the licence for Kaftrio, a disease-modulating therapy for cystic fibrosis, to children under 12.
- Changing the lives of children with a new cystic fibrosis treatmenton January 12, 2022 at 5:56 am
The National Health Service (NHS) has announced a new cystic fibrosis treatment is now available, which will benefit hundreds of children.
- ‘Revolutionary’ cystic fibrosis treatment extended to more than 1,000 childrenon January 12, 2022 at 4:57 am
A drug which has transformed the lives of thousands of cystic fibrosis sufferers will now be offered to children on the NHS. Kaftrio, which tackles the underlying causes of the disease as well as its ...
- ‘Miracle’ Cystic Fibrosis treatment for children on the NHSon January 11, 2022 at 10:35 pm
Hundreds of children are set to benefit from a ‘miracle’ treatment for cystic fibrosis, which has already changed the lives of thousands of people, the NHS has announced today. Patients here were some ...
- Cystic Fibrosis Drugs Market 2022 : Key Players Change the View of the Global Face of Industry by 2026 with Leading Regions and Countries Dataon January 11, 2022 at 6:58 pm
Global “Cystic Fibrosis Drugs Market" is expected to grow at a steady growth during the forecast period 2021-2025, ...
- Cystic fibrosis treatment extended to more than 1,000 children on NHSon January 11, 2022 at 4:01 pm
A treatment for people who have cystic fibrosis is now available to more than 1,000 children on the NHS Kaftrio, which tackles the underlying causes of the disease as well as symptoms, has been ...
- Cystic Fibrosis Market is Projected to Register a CAGR of 13.5% in the Forecast Periodon January 10, 2022 at 5:08 am
The global cystic fibrosis market size during the forecast period 2013 to 2025 will register growth at a CAGR of 13 5 The market for cystic fibrosis is set to reach US 12 943 1 million by 2025 ...
via Bing News
